An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd)

Once-weekly carfilzomib at 56 mg/m plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT study (NCT04191616) evaluated efficacy/safety of weekly carfilzomib, pomalidomide, and dexamethasone (KP...

Descripción completa

Detalles Bibliográficos
Autores: Perrot, Aurore, Delimpasi, Sosana, Spanoudakis, Emmanouil, Frølund, Ulf, Belotti, Angelo, Oriol, Albert|||0000-0001-6804-2221, Moreau, Philippe|||0000-0003-1780-8746, McFadden, Ian, Xia, Qing, Arora, Mukta|||0000-0001-9362-0556, Dimopoulos, Meletios|||0000-0001-8990-3254
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302172
Acceso en línea:https://ddd.uab.cat/record/302172
https://dx.doi.org/urn:doi:10.1080/10428194.2024.2322030
Access Level:acceso abierto
Palabra clave:Carfilzomib
Lenalidomide
Refractory
Triple-class
Relapsed/refractory multiple
Myeloma
Pomalidomide
Descripción
Sumario:Once-weekly carfilzomib at 56 mg/m plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT study (NCT04191616) evaluated efficacy/safety of weekly carfilzomib, pomalidomide, and dexamethasone (KPd) in early RRMM patients refractory to lenalidomide. All 52 treated patients were refractory to prior treatment, and 19 (37%) were triple-class refractory. Overall response rate (ORR; primary endpoint) was 58% (35% ≥ very good partial response, 6% ≥ complete response); median response duration was 20.3 months. Minimal residual disease negativity (10) was achieved in 10% of patients. Median progression-free survival was 11.1 months; median overall survival was 18.8 months. Adverse events (AEs) were consistent with the known safety profile including grade ≥3 treatment-emergent AEs reported in 67% of patients. Although the primary endpoint of ORR was not met, KPd showed meaningful clinical benefits in lenalidomide-refractory RRMM patients, including those who were daratumumab-refractory and/or triple-class refractory.

Similares en LA Referencia